Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Bladder Cancer

  Free Subscription

Articles published in Eur J Cancer

Retrieve available abstracts of 12 articles:
HTML format

Single Articles

    May 2021
  1. ROUANNE M, Arpaia N, Marabelle A
    CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer.
    Eur J Cancer. 2021 May 7. pii: S0959-8049(21)00222.

    March 2021
  2. GROENEVELD CS, Fontugne J, Cabel L, Bernard-Pierrot I, et al
    Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Eur J Cancer. 2021;148:181-189.
    PubMed     Abstract available

    May 2020
  3. MATSUMOTO S, Kijima T, Matsuoka Y, Yamamoto M, et al
    A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab.
    Eur J Cancer. 2020;131:104-107.

    January 2019
  4. ROUANNE M, Betari R, Radulescu C, Goubar A, et al
    Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer.
    Eur J Cancer. 2019;108:111-119.
    PubMed     Abstract available

    June 2018
  5. NECCHI A, Raggi D, Giannatempo P, Alessi A, et al
    Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.
    Eur J Cancer. 2018;96:128-130.

    May 2018
  6. CAPURSO G, Archibugi L, Tessieri L, Petrone MC, et al
    Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?
    Eur J Cancer. 2018;95:123-126.

    April 2018
  7. ANDREASSEN BK, Grimsrud TK, Haug ES
    Bladder cancer survival: Women better off in the long run.
    Eur J Cancer. 2018;95:52-58.
    PubMed     Abstract available

    February 2017
    Bladder cancer and smoking with special reference to education.
    Eur J Cancer. 2017;75:1-2.

    October 2016
  9. VAN DER HEIJDEN AG, Mengual L
    Reply to letter commenting on: A five-gene expression signature to predict progression in T1G3 bladder cancer.
    Eur J Cancer. 2016 Oct 30. pii: S0959-8049(16)32449.

  10. ORSOLA A, Mullane SA, Bellmunt J
    Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernandez PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer
    Eur J Cancer. 2016 Oct 30. pii: S0959-8049(16)32448.

  11. GOOSSENS ME, Zeegers MP, van Poppel H, Joniau S, et al
    Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial.
    Eur J Cancer. 2016;69:9-18.
    PubMed     Abstract available

  12. HERMANS TJ, Fransen van de Putte EE, Horenblas S, Meijer RP, et al
    Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.
    Eur J Cancer. 2016;69:1-8.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.